New peer-reviewed evidence shows Diopsys® ffERG/Flicker parameters significantly correlate with other markers of diabetic retinopathy, such as fluorescein angiography.1 This correlation may allow clinicians to establish an easy, useful surrogate biomarker with an in-office, non-invasive test that is sensitive to disease progression and improvement.2-7
Please join Dr. Wroblewski to learn how this objective, functional test may help doctors determine therapeutic efficacy, offering a more subtle and precise look into treatment – whether to continue therapy, adjust dosing, or to discontinue.
1. Wroblewski, John J., et al. Reproducibility of Fixed-Luminance and Multi-Luminance Flicker Electroretinography in Patients With Diabetic Retinopathy Using an Office-Based Testing Paradigm. Journal of Diabetes Science and Technology, Oct. 2019, doi:10.1177/1932296819882719. 2. Holm K, et al. Peripheral retinal function assessed with 30-Hz flicker seems to improve after treatment with Lucentis in patients with diabetic macular oedema. Doc Ophthalmol. 2015;131:43-51. 3. Pescosolido N, et al. Role of Electrophysiology in the Early Diagnosis and Follow-Up of Diabetic Retinopathy. J Diabetes Res. 2015;doi.org/10.1155/2015/319692. 4. Tzekov R, et al. The Electroretinogram in Diabetic Retinopathy Surv Ophthalmol. 1999;doi:10.1016/s0039-6257(99)00063-6. 5. Chous AP, et al. The Diabetes Visual Function Supplement Study (DiVFuSS). Br J Ophthalmol. 2016;doi:10.1136/bjophthalmol-2014-306534. 6. Kowluru RA, et al. Beneficial effects of the nutritional supplements on the development of diabetic retinopathy. Nutr Metab. 2014;doi:10.1186/1743-7075-11-8
